35 results about "Cmv infections" patented technology

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

The invention discloses a method for synchronously detecting three kinds of viruses on tobacco through triple one-step method RT-PCR (Reverse Transcription Polymerase Chain Reaction). The method is characterized by being used for synchronously detecting TMV (Tobacco Mosaic Virus), PVY (Potato Virus Y) and CMV (Cucumber Mosaic Virus), the method comprises the following steps of screening and comparing conservation areas in a virus gene group, artificially screening and synthesizing specificity primers suitable for composite RT-PCR of three kinds of virus diseases; analyzing to obtain TMV, PVY and CMV infection tobacco leaf samples; and integrating enzymes and a buffer solution required by a reverse transcription and a PCR (Polymerase Chain Reaction), and establishing a method for compositely detecting the TMV, PCY and CMV infection of tobacco leaves based on one-step method RT-PCR through optimization of reaction conditions. The triple one-step method RT-PCR utilized by the invention has the advantages of simple and convenient operation, time and labor saving, reliable result and low cost; simultaneously, the probability of cross-contamination of samples in an operation process canbe effectively reduced, and the monitoring on the TMV, PVY and CMV in tobacco agricultural production has wide application prospect.

This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins and DNAS, as well as vaccines comprising the proteins and DNAs, including cellular vaccines and vectors. Other embodiments of the invention relate to methods of enhancing immune response and vaccinating against CMV, including gene therapy methods and vectors.

The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and / or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.

The invention provides compositions and methods useful for early detection of congenital CMV infection, predicting the likelihood and severity of congenital CMV disease, and monitoring the efficacy of therapeutic approaches. Compositions of the present invention include biomarkers that are differentially expressed in CMV-infected mothers and fetuses compared to uninfected individuals.

Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM / gN or gO.

The present invention relates to the field of cytomegalovirus (CMV) infection. In particular the present invention relates to highly specific immunotoxins useful in treating diseases related to CMV infection. CMV encodes chemokine receptors that undergo constitutive internalization. Thus CMV infected cells can be targeted specifically with immunotoxins with high affinity to CMV encoded constitutively internalizing receptors. This will ensure efficient uptake of the immunotoxin by the CMV infected cell, and thereby ensure the death of the infected cell with a minimum of unwanted toxicity and side effects. Furthermore, the invention relates to a way of inhibiting CMV replication and / or growth by using immunotoxins by targeting constitutively internalizing CMV encoded receptors.

Described herein are materials and methods for stratifying risk for reactivation of a latent viral infection, such as CMV infection. The methods are particularly useful for immune compromised subjects. Also described herein are interventions, including therapeutic, prophylactic, and monitoring interventions, for subjects determined to be at elevated risk.

The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and / or preventing CMV infections in a patient in need thereof.

The method for simultaneously detecting three viruses on tobacco by triple one-step RT-PCR is characterized in that: it is a method for simultaneously detecting tobacco common mosaic virus, potato virus Y and cucumber mosaic virus, and the method includes screening and comparison of conserved virus genomes Region, manual screening and synthesis of compound RT-PCR specific primers suitable for three viral diseases; analysis of TMV, PVY, CMV infected tobacco leaf samples; integration of enzymes and buffers required for reverse transcription and PCR reactions, through optimization of reaction conditions, To establish a method based on one-step RT-PCR combined detection of TMV, PVY and CMV infection in tobacco leaves. The triple one-step RT-PCR reaction adopted in the present invention has the advantages of simple and convenient operation, time-saving and labor-saving, reliable results, and low cost, and can effectively reduce the possibility of cross-contamination of samples during the operation process. , PVY, CMV monitoring and monitoring has a wide range of application prospects.

The present invention provides a method for expanding and culturing CD8 T cells, that is, in the presence of the following substances, inducing, expanding and culturing CD8 T cells: K3EC cells; the K3EC cells express CD2 ligand CD58 and NKG2D ligand MICA / B K562 engineered cells with CD137 ligand CD137L are used to provide the second signal of co-stimulatory receptors to activate CD8 T cells; peptide overlapping libraries of target antigens are used to provide TCR first signals to activate CD8 T cells. This method realizes the rapid and efficient expansion of antigen (CMV-pp65)-specific CD8 T cells; the CD8 T cells obtained through the expansion have high clinical application value in the prevention and treatment of CMV infection and the treatment of CMV-related cancers.

The present invention provides novel inhibitors of inflammation and methods for treating inflammation by using these inhibitors. More specifically, the present invention provides transcription inhibitors, i.e., peptide fragments derived from internal regions of the Cytomegalovirus (CMV) IE2 protein that can inhibit production of inflammatory cytokines, e.g., Interleukin 1 beta (IFN-l beta) and the methods for treating inflammatory diseases and CMV infection and related disorders, by using the IE2 fragments. An pharmaceutical composition comprising the transcription inhibitor are also provided.

The present disclosure provides a method for inhibiting cytomegalovirus (CMV) replication in a cell infected with CMV, the method comprising contacting the cell with a bisbenzimidazole compound. The present disclosure provides a method of treating a CMV infection in an individual, the method comprising administering to the individual an effective amount of a bisbenzimidazole compound.

The invention relates to a kit and a method for detecting CMV infection in a trace biological sample of an eye, and relates to a molecular detection technology for eye viral infections, in particularto a method for extracting DNA from the trace biological sample, wherein the trace biological sample refers to a liquid sample with a volume not exceeding 10mu l-200mu l or a solid sample with a volume not exceeding 1mm<3>. By use of the extracted DNA as a PCR detection template, the eye viral infections can be detected with an accuracy of 80% or more, and the method provides a reliable basis forsubsequent appropriate treatment methods and reduces the blindness of the treatment methods.

In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM / gN or gO.